This Stock Could Rise Over the Next 10 Years

Neovasc Inc. (TSX:NVCN)(NASDAQ:NVCN) is seeking strategic alternatives and alliances to build on the growing enthusiasm in the market for the company’s products.

| More on:

Neovasc (TSX:NVCN)(NASDAQ:NVCN) is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace. The company’s products include Neovasc Reducer, for the treatment of refractory angina, which is not currently commercially available in the United States, and the Tiara for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the U.S., Canada, Israel, and Europe.

The company’s core strategy is to focus on establishing confidence with Neovasc’s stakeholders, and to continue the development and commercialization of the company’s products. Through the Tiara and the Reducer, Neovasc is working on providing minimally invasive medical devices for a cardiovascular market that the company believes is both growing and underserved by current treatment solutions. Neovasc was incorporated in 2000 and is headquartered in Richmond, Canada.

Treatment of refractory angina

With regards to the Reducer, the company is continuing therapy development and has successfully supplemented a clinical study with additional clinical experience. Neovasc is targeting a commercial launch in Europe. Improving revenue growth in Europe and providing reimbursement initiatives in other international markets could significantly increase the company’s stock price.

Neovasc is also seeking strategic alternatives and alliances to build on the growing enthusiasm in the market for the Reducer in order to broaden and deepen therapy penetration in Europe and the Middle East. The company is evaluating several studies with U.S. Food and Drug Administration (FDA) and approvals could result in a sales boost for Neovasc.

Treatment of mitral valve disease

The company’s clinical experience of the Tiara was successful, and the clinical data study was used by the company to file for commercialization. Enrollment in the clinical study was closed in 2019 with a total of 27 patients being treated for the next five years. The company is targeting a European regulatory decision for Tiara in the first half of 2021, although it provides no assurance that European regulatory approval will be granted in the time frame anticipated by management or granted at any time in the future. If the development of the Tiara system for preclinical bench and animal studies leads to successful completion, this could be followed by human compassionate use in the second half of 2021.

Robust product pipeline

Product development activities have recently started at the company for the development of the Tiara system, focused on a suitable and novel transfemoral delivery system. Further, the company is working on few important but minor changes to the Tiara valve to make it deliverable and to further penetrate the patient population. These development activities are taking place at the company’s Vancouver facility. Furthermore, engineering resources are continuing to support manufacturing for both the Reducer system, and the Tiara system for clinical studies.

Neovasc’s specialty medical devices products could have a revolutionary impact on the cardiovascular industry in Europe, Canada, the U.S., and internationally. The company’s Tiara technology is likely to be widely used for the transcatheter treatment of mitral valve disease. Further, Neovasc’s Reducer is also to be likely used for the treatment of refractory angina in the future.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Nikhil Kumar has no position in any of the stocks mentioned.

More on Investing

A worker overlooks an oil refinery plant.
Energy Stocks

What to Know About Canadian Energy Stocks for 2025

Today, I'll explore tariffs, pipelines, and profit potential on TSX energy stocks for 2025, and how Suncor stock and two…

Read more »

An investor uses a tablet
Bank Stocks

Better Banking Stock: Royal Bank vs TD Bank?

Royal Bank has outperformed TD in recent years. Will 2025 be different?

Read more »

Canadian Dollars bills
Dividend Stocks

Invest $22,000 in 2 TSX Stocks for $1,279 in Passive Income

Passive income doesn't need to be difficult or costly, and these two stocks offer it up in spades!

Read more »

Piggy bank with word TFSA for tax-free savings accounts.
Dividend Stocks

The Best Canadian Dividend Stocks to Buy and Hold Forever in a TFSA

These Canadian stocks all pay reliable dividends and consistently grow their earnings, making them three of the best to buy…

Read more »

Stocks for Beginners

The Best Stocks to Invest $25,000 in Right Now

Got a bunch of cash to deploy? These four Canadian stocks would make an excellent start for a long-term investment…

Read more »

Dividend Stocks

Got $1,000? 3 REITs to Buy and Hold Forever

Do you want some REITs to buy and hold forever? Here’s a look at a trio of options to consider…

Read more »

data analyze research
Dividend Stocks

2 Stocks I Loaded Up on in 2024 for Long-Term Wealth

A tech giant and a renewable energy giant were strong picks in 2024 and will continue to be strong through…

Read more »

dividend growth for passive income
Dividend Stocks

Need Decades of Passive Income? 2 Stocks to Buy Without Delay

These two dividend stocks offer it all. Stable passive income, with growth opportunities already on the way.

Read more »